RXRX - NASDAQ
Recursion Pharmaceuticals, Inc.
$3.47
-8.4%Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
At a Glance
Live Snapshotrxrx
Other Current Liabilities
Last Annual Value
70.23M
3-Year CAGR
51%
5-Year CAGR
87%
10-Year CAGR
45%
Recursion Pharmaceuticals, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX | 70.23M | 43.5% | 43.0% | N/A | |
 89bio, Inc. NASDAQ:ETNB | 6.87M | -21.6% | -0.4% | N/A | |
 Sarepta Therapeutics, Inc. NASDAQ:SRPT | 359.86M | 26.3% | 26.6% | 31.3% | |
 Liquidia Corporation NASDAQ:LQDA | 73.20M | 104.6% | 87.5% | 51.3% | |
 Cogent Biosciences, Inc. NASDAQ:COGT | 52.90M | 72.5% | 70.9% | 84.1% | |
 ImmunityBio, Inc. NASDAQ:IBRX | 25.42M | 11.6% | 9.0% | 12.6% | |
 Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 18.20M | -7.8% | -1.7% | -2.9% | |
 Denali Therapeutics Inc. NASDAQ:DNLI | 85.47M | 58.2% | 35.1% | 61.7% | |
 Arcus Biosciences, Inc. NYSE:RCUS | 196.00M | 71.3% | 45.3% | 76.1% | |
 Beam Therapeutics Inc. NASDAQ:BEAM | 36.34M | -28.8% | -9.8% | N/A |
Recursion Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your RXRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.